Pulmonx Q2 EPS $(0.43), Inline, Sales $17.19M Beat $15.91M Estimate
Portfolio Pulse from bharat@benzinga.com
Pulmonx (NASDAQ:LUNG) reported Q2 earnings per share (EPS) of $(0.43), in line with analyst consensus. This is a 7.5% decrease from the same period last year. However, the company's quarterly sales of $17.19M beat the analyst consensus estimate of $15.91M by 8.07%, marking a 23.25% increase from last year.
August 04, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pulmonx's Q2 earnings met expectations, but sales exceeded estimates and showed significant YoY growth.
Pulmonx's Q2 earnings were in line with expectations, which is generally neutral for the stock. However, the company's sales beat estimates by a significant margin and showed strong YoY growth, which is typically positive for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100